Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
Topics & Concepts
LapatinibMedicineTrametinibKRASRashColorectal cancerInternal medicineLung cancerDosingCancerOncologyPancreatic cancerPharmacokineticsPharmacologyGastroenterologyBreast cancerMAPK/ERK pathwayBiologyTrastuzumabKinaseCell biologyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways